Mesoblast Posts $115M in First Full-Year Ryoncil Revenue as Cash Burn Plunges to $13.4M in H2
MESO is trading near its 52-week low of $12.66 (12% above the low).
Summary
Mesoblast reported $115M in first full-year Ryoncil revenue, slashed H2 operating cash burn to $13.4M, and ended with $103M cash — enough for over 11 quarters. Key pipeline milestones include completing enrollment in the Phase 3 CLBP trial and FDA acceptance of the rexlemestrocel-L BLA.
Key Events · Earnings and Guidance · MESO
-
Ryoncil Revenue Hits $115M in First Full Year
Fourth-quarter net revenue of $36M lifted the full-year total to $115M, with $66.5M coming in the second half — underscoring strong commercial uptake in pediatric SR-aGvHD.
-
Cash Burn Drops to $13.4M in H2
Full-year net operating cash spend was $43.8M, but the second half required only $13.4M, reflecting improving operating leverage as revenue scales.
-
Cash Runway Extends Beyond 11 Quarters
Ended June 30, 2026 with $103M cash after drawing $50M from the existing facility to retire all maturing debt; at the Q4 burn rate of $9.3M, runway exceeds 11 quarters.
-
Phase 3 CLBP Trial Fully Enrolled
Achieved target of at least 300 patients treated in the pivotal rexlemestrocel-L trial for chronic low back pain; 12-month primary endpoint data to follow.
Analysis · MESO · Life Sciences
A strong first full year of Ryoncil sales delivered $115 million, with the fourth quarter alone contributing $36 million — an annualized pace that points toward blockbuster territory. Cash burn contracted sharply to just $13.4 million in the second half, stretching the runway beyond 11 quarters on a $103 million cash balance. The company also cleared key pipeline milestones: the Phase 3 CLBP trial reached its 300-patient enrollment target, and the FDA accepted the BLA for rexlemestrocel-L in LVAD heart failure. Drawing down the remaining $50 million from the existing credit facility to retire all maturing debt removes a near-term refinancing overhang. Taken together, the figures depict a biotech transitioning from cash-intensive development to self-funding commercial growth, with multiple catalysts ahead.
At the time of this filing, MESO was trading at $14.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $12.66 to $21.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.